Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 4, 2015, Pages 454-462

  Hesseling, A C ^a   Jaspan, H B ^b,c   Black, G F ^a   Nene, N ^a   Walzl, G ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

ELISA; IFN ; Randomised vaccine trial; Response; TB

Indexed keywords

BCG VACCINE; CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; TUBERCULIN;

ARTICLE; BACTERIAL IMMUNITY; BCG VACCINATION; CELLULAR IMMUNITY; CHILD HEALTH CARE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOREGULATION; INFANT; MYCOBACTERIUM TUBERCULOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO TREATMENT; TUBERCULIN TEST; TUBERCULOSIS; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; FEMALE; IMMUNOLOGY; MALE; VACCINATION;

ANTIBODY FORMATION; BCG VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INTERFERON-GAMMA; MALE; TUBERCULOSIS; VACCINATION;

EID: 84925597657     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0608     Document Type: Article

References (30)

1. Cotton M F, Schaaf H S, Lottering G, Weber H L, Coetzee J, Nachman S. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis 2008; 12: 225-227.
2. Madhi S, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365: 29-39.
3. Rodrigues L C, Diwan V K, Wheeler J G. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 1154-1158.
4. Trunz B, Fine P, Dye C. et al. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of costeffectiveness. Lancet 2006; 367: 1173-1180.
5. Hussey G D, Watkins M L V, Goddard E A, et al. Neonatal mycobacterial specific cytotoxic T-lymphocyte and cytokine profiles in response to distinct BCG vaccination strategies. Immunology 2002; 105: 314-324.
6. Mansoor N, Abel B, Scriba T J, et al. Significantly skewed memory CD8(+) T cell subsets in HIV-1 infected infants during the first year of life. Clin Immunol 2008; 130: 280-289.
7. Lalor M K, Ben-Smith A, Gorak-Stolinska P, et al. Population differences in immune responses to bacille Calmette-Guérin vaccination in infancy. J Infect Dis 2009.199: 795-800.
8. Weir RE, Gorak-Stolinska P, Floyd S, et al. Persistence of the immune response induced by BCG vaccination. BMCInfect Dis 2008; 8: 9.
9. Gorak-Stolinska P, Weir R E, Floyd S, et al. Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 2006; 24: 5726-5733.
10. Kagina B M, Abel B, Scriba T J, et al.; other members of the South African Tuberculosis Vaccine Initiative. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182: 1073-1079.
11. Forbes E K, Sander C, Ronan E O, et al. Multifunctional, highlevel cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181: 4955-4964.
12. Mittrücker H, Steinhoff U, Köhler A, et al. Poor correlation between BCG vaccination-induced T-cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 2007; 104: 12434-12439.
13. Day C L, Abrahams D A, Leruma L, et al. Functional capacity of Mycobacterium tuberculosis-specific T-cell responses in humans is associated with mycobacterial load. J Immunol 2011; 187: 2222-2232.
14. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gammareceptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335: 1956-1961.
15. Scriba T J, Kalsdorf B, Abrahams D-A, et al. Distinct, specific IL-17- and IL-22-producing CD4+ T-cell subsets contribute to the human antimycobacterial immune response. J Immunol 2008; 180: 1962-1970.
16. Sutherland J S, Adetifa I M, Hill P C, Adegbola R A, Ota M O C. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39: 723-729.
17. Flynn J L, Chan J, Triebold K J, Dalton D K, Stewart T A, Bloom B R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254.
18. Hesseling A C, Johnson L F, Jaspan H, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87: 505-511.
19. Hesseling A C, Caldwell J, Cotton M F, et al. BCG vaccination in South African HIV-exposed infants: risks and benefits. S Afr Med J 2009; 99: 88-91.
20. Hesseling A C, Cotton M F, Marais B J, et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine 2007; 25: 6565-6568.
21. Van Rie A, Madhi S A, Heera J R, et al. Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers. Clin Vaccine Immunol 2006; 13: 246-252.
22. Kidzeru E B, Hesseling A C, Passmore J A, et al. In-utero exposure to maternal HIV infection alters T cell immune responses to vaccination in HIV-uninfected infants. AIDS 2014; 28: 1421-1430.
23. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005. Clin Infect Dis 2007; 45: 241-249.
24. Kali P B N, Gray G E, Violari A, Chaisson R E, McIntyre J A, Martinson N A. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr 2006; 42: 379-381.
25. Kagina B, Abel B, Hussey G D, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T-cell response Vaccine 2009; 27: 5488-5495.
26. Ota M, Vekemans J, Schlegel-Haueter S E, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168: 919-925.
27. Burl S, Adetifa U J, Cox M, et al. Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 presponses but leads to comparable myobacterial responses at 9 months of age. J Immunol 2010; 185: 2620-2628.
28. Tchakoute C T, Hesseling A C, Kidzeru E B, et al. Delaying BCG vaccination until 8 weeks of age results in robust BCGspecific T-cell responses in HIV-exposed infants. J Infect Dis 2015; 211: 338-346.
29. Jones C, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling A C. Infants exposed to HIV at birth but not infected may have lower antibody levels against certain diseases. JAMA 2011; 305: 535-634.
30. Kuhn L, Coutsoudis A, Moodley D, et al. Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers. Pediatr Res 2001; 50: 412-416.